Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 8/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3167747 | 0.82 | SMPD1 (0.42) | SMPD1CES1FDPSGGPS1MEN1 | |
| SCHEMBL8337452 | 0.82 | SMPD1 (0.42) | SMPD1CES1FDPSGGPS1MEN1 | |
| SCHEMBL27932896 | 0.82 | SMPD1 (0.41) | SMPD1CES1FDPSGGPS1HTT | |
| SCHEMBL14359444 | 0.78 | LPAR3 (0.41) | SMPD1CES1FDPSGGPS1LPAR1 | |
| SCHEMBL30634500 | 0.78 | CES1 (0.47) | CES1MEN1THRBHTTKMT2A | |
| SCHEMBL29435127 | 0.77 | MEN1 (0.41) | SMPD1CES1FDPSGGPS1MEN1 | |
| SCHEMBL8769729 | 0.76 | CES1 (0.45) | CES1MEN1THRBHTTKMT2A | |
| SCHEMBL4582470 | 0.76 | SMPD1 (0.55) | SMPD1FDPSGGPS1THRB | |
| SCHEMBL15308094 | 0.76 | CES1 (0.45) | CES1MEN1THRBHTTKMT2A | |
| SCHEMBL7523594 | 0.76 | SMPD1 (0.55) | SMPD1FDPSGGPS1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082549-A1 | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections | JOMAA HASSAN (DE) | 2004-04-29 | — | — | US | disclosed |
| US-6680308-B1 | ADMINISTERING N-(FORMYL OR ACETYL)-N-HYDROXYLAMINO)-ALKYLPHOSPHONIC ACID DERIVATIVE AS VIRICIDE, PARASITICIDE OR FUNGICIDE | BIOAGENCY AG (DE) | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082549-A1 | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections | PON1, DDT, GPX1 | SMPD1 47/4885CES1 20/4885FDPS 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.